tetano
Editor, Senior Moderator
Clin Transl Sci. 2020 Mar 25. doi: 10.1111/cts.12790. [Epub ahead of print]
Optimizing COVID-19 candidate therapeutics: Thinking Without Borders.
Rayner CR[SUP]1[/SUP], Smith PF[SUP]1[/SUP], Hershberger K[SUP]1[/SUP], Wesche D[SUP]1[/SUP].
Author information
Abstract
This commentary seeks to share some key insights relevant to optimizing COVID-19 candidate therapeutics that were learned from attempts to optimize anti-infective posology in settings where quality and timely availability of data is challenging, with particular focus on influenza, including experiences from H5N1 and pH1N1 outbreaks.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; antiviral; clinical pharmacology; coronavirus; drug development
PMID:32212378DOI:10.1111/cts.12790
Optimizing COVID-19 candidate therapeutics: Thinking Without Borders.
Rayner CR[SUP]1[/SUP], Smith PF[SUP]1[/SUP], Hershberger K[SUP]1[/SUP], Wesche D[SUP]1[/SUP].
Author information
Abstract
This commentary seeks to share some key insights relevant to optimizing COVID-19 candidate therapeutics that were learned from attempts to optimize anti-infective posology in settings where quality and timely availability of data is challenging, with particular focus on influenza, including experiences from H5N1 and pH1N1 outbreaks.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; antiviral; clinical pharmacology; coronavirus; drug development
PMID:32212378DOI:10.1111/cts.12790